CNSP (CNS Pharmaceuticals) Buyback Yield %: -74.86 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNSP CNS Pharmaceuticals Inc CNSP
29 GF Score
Price $5.04
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Buyback Yield %?

CNS Pharmaceuticals CNSP +3.92% 29 Buyback Yield % is -74.86 as of Jul. 18, 2026. GuruFocus rates CNSP with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 740 Biotechnology companies, CNS Pharmaceuticals ranks worse than 88.78% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

CNS Pharmaceuticals's current buyback yield was -74.86%.

CNS Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Buyback Yield % Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 -274.23 -422.60

CNS Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -722.14 -620.53 -358.40 -422.60 -284.48

CNSP vs NXTC, ENVB, CDIO: Buyback Yield % Comparison

For the Biotechnology subindustry, CNS Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNS Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's Buyback Yield % falls into.


CNSP
29GF Score
CNS Pharmaceuticals Inc CNSP
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

CNS Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.002 + 14.046) / 3.32325
=-422.60%

CNS Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.001 + 5.515) / 1.93829
=-284.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -74.86 mean?
CNS Pharmaceuticals (CNSP) has a Buyback Yield % of -74.86 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CNS Pharmaceuticals and its competitors. According to the industry distribution chart, CNS Pharmaceuticals ranks #657 out of 740 companies in the Biotechnology industry, placing it in the top 88.8%.
Is CNS Pharmaceuticals' Buyback Yield % too high?
CNS Pharmaceuticals' current Buyback Yield % is -74.86. Based on the distribution chart, CNS Pharmaceuticals ranks #657 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CNS Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Buyback Yield % compare to NXTC and ENVB?
According to the Biotechnology industry distribution chart, CNS Pharmaceuticals ranks #657 out of 740 companies for Buyback Yield %. This places CNS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current Buyback Yield % is -74.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (CNSP) has a current Buyback Yield % of -74.86. The current Buyback Yield % is -74.86. CNS Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CNS Pharmaceuticals (CNSP), the current Buyback Yield % is -74.86 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
29GF Score

Get the complete analysis for CNSP

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.04
Price